Highlights Ventyx Biosciences, Inc.

Equities

VTYX

US92332V1070

Real-time Estimate Cboe BZX Other stock markets 11:51:52 04/06/2024 pm IST			5-day change	1st Jan Change
4.92 ^USD	-0.61%		-4.09%	+99.19%

23/05	Transcript : Ventyx Biosciences, Inc. Presents at UBS Obesity Therapeutics Day, May-23-2024 12:00 PM
16/05	Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ventyx Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
North American Morning Briefing : Stock Futures -2-	13/03	DJ
Ventyx Biosciences, Inc. Reports Clinical Data for Its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event	11/03	CI
Ventyx Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Ventyx Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02	CI
Ventyx Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Ventyx Biosciences, Inc. Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis	07/11	CI
Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-To-Severely Active Ulcerative Colitis	10/23/10	CI
Ventyx Biosciences Q2 Net Loss Widens	11/23/11	MT
Ventyx Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Ventyx Biosciences, Inc. Announces Initiation of Dosing in A Phase 1 Trial of VTX3232, A Novel CNS-Penetrant NLRP3 Inhibitor	14/23/14	CI
Ventyx Biosciences Q1 Loss Widens	12/23/12	MT
Ventyx Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Ventyx Biosciences, Inc. acquired Zomagen Biosciences Ltd.	14/23/14	CI
VENTYX BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	24/23/24	AQ
Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors	12/23/12	AQ
Ventyx Biosciences, Inc Announces Dosing of the First Patient in the Phase 2 Serenity Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis	02/22/02	CI
VENTYX BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	05/22/05	AQ
Ventyx Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	04/22/04	CI
Sector Update: Health Care Stocks Finding Modest Buying Support Late, but Still Unable to Reach Positive Ground	17/22/17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ventyx Biosciences, Inc.

Equities

VTYX

US92332V1070

Highlights

Filters